Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | LINKER-MM1: linvoseltamab, a bispecific antibody, in R/R multiple myeloma

Madhav Dhodapkar, MBBS, Emory University School of Medicine, Atlanta, GA, provides an overview of the Phase II LINKER-MM1 trial (NCT03761108), which assessed the BCMA×CD3 bispecific antibody linvoseltamab in heavily pretreated patients with relapsed/refractory (R/R) multiple myeloma. Promising efficacy was reported, where multiple very good partial responses (VGPR) were achieved in a majority of patients. The investigational drug additionally was well tolerated, where adverse events were similar to that of similar antibodies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


BMS, Sanofi, Genentech, Lava Therapeutics